CClinicalTrials.gg
WithdrawnNCT03299387INSTANTUpdated Jun 6, 2019

INtravesical Antimicrobial Agents v STANDard Oral Antibiotics for the Treatment of Acute UTI in Women With rUTI

A Phase 4 interventional study of Nitrofurantoin and Gentamicin in Urinary Tract Infections, sponsored by Mayo Clinic. Withdrawn. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-06.

Sponsored by Mayo Clinic · Phase 4, Interventional, and Treatment

Why this study was withdrawn
Study never recruited
Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Women have problems with oral antibiotics, including vagina and bowel infections. Also, bacteria causing urinary infections are becoming more resistant to oral antibiotis. Placement of antibiotic directly into the bladder does not cause these problems and are at doses that are may be able to stop bacteria from being resistant to antibiotics.

Read the detailed description

Each participant once enrolled returns with an active Urinary Tract Infection (UTI), confirmed by urine void. Participants will complete an UTI questionnaire, and if consistent with a simple non-febrile UTI will be randomized to one of two arms: oral nitrofurantoin treatment for 7 days, or intravesical gentamicin instillation once a day for three days. Patients will be followed for symptom relief with a repeat voided urine in 7 to 10 days, and with a repeated questionnaire for symptom relief.

02

Conditions studied

  • Urinary Tract Infections

Keywords

  • urinary tract
  • infection
  • recurrent
  • women
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Ability to understand study procedures and to comply with them for the entire length of the study.

Exclusion criteria

Exclusion Criteria:

  • Patients who report that they are pregnant.
  • Patients with a positive urine pregnancy test
  • Patients with a history of renal transplantation.
  • Patients with bladder augmentation procedures using bowel.
  • Patients with poorly controlled Type II diabetes, Hgb A1C >6.5%
  • Patients with spinal cord injury, ASIA Impairment Scale of C or higher.
  • Patients with pelvic surgery within 6 months.
  • Patients with urologic procedure within 6 months.
  • Patients with a history of reconstructive urologic surgery, such as reflux, congenital abnormality.
  • Immunocompromised patients being treated for malignancy or a history of actively treated malignancy within 5 years.
  • Patients with active systemic autoimmune disease.
  • Patients on systemic immunosuppression.
  • Use of antibiotic prophylaxis within 6 months
  • Use of antibiotics within 10 days of active infection
  • Allergy/sensitivity to gentamicin or nitrofurantoin.
  • Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  • Inability or unwillingness of individual to give written informed consent.
04

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Oral Nitrofurantoin

    Participants will randomized to oral nitrofurantoin

    Drug: Nitrofurantoin

  • Active comparator
    Intravesical Gentamicin

    Participants will be randomized to intravesical gentamicin

    Drug: Gentamicin

Interventions

  • DrugNitrofurantoin

    Participants will receive oral Nitrofurantoin 100 mg twice daily for 7 days

    Also known as: Macrobid, Furadantin, Macrodantin

  • DrugGentamicin

    Participants will receive intravesical via catheter Gentamicin solution 25 mg in 50cc for 3 days

    Also known as: Gentak, Garamycin

05

What researchers measure

Primary outcomes

  1. Change in microbiologic effect of a chronic acute Urinary Tract Infection

    Microbiological culture growth of susceptible organisms obtained on day 0, compared with voided urine culture as no growth in 24-48 hours obtained at 7-10 days

    Time frame: baseline, 7-10 days

  2. Change in symptomatic relief of a chronic acute Urinary Tract Infection

    Completion of a Symptom Urinary Tract Questionnaire. Tracking the symptoms in the past 24 hours. Indicating how severe and how bothersome they were. Severe ranging from 0 (Did not have) to 3 (Severe). Bothersome ranging from 0 (Not at all) to 3 (A lot)

    Time frame: baseline, 7-10 days

Secondary outcomes

  1. To establish the clinical FTE needs for providing urgent intravesical treatments

    Nursing needs to provide intravesical treatments of acute Urinary Tract Infections (UTI) in women with chronic recurrent UTIs. Measured in amount of participants and FTE requirement for nursing staff.

    Time frame: baseline, through stufy completion, an average of one year

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03299387
Lead sponsor
Mayo Clinic
Responsible party
Deborah J. Lightner (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Oct 3, 2017
Start date
Jun 28, 2017
Primary completion
Jul 5, 2018
Completion
Jul 5, 2018
Last update
Jun 6, 2019

Study contacts

Deborah Lightner, MD
principal investigator · Mayo Clinic
Audrey N Schuetz, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion